Advanced search
Publication Cover
International Journal of Neuroscience Volume 132, 2022 - Issue 7
Submit an article Journal homepage
281
Views
13
CrossRef citations to date
0
Altmetric
Case Reports

Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma

Olga E. Makria Department of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Foteinos-Ioannis Dimitrakopoulosb Division of Oncology, Department of Medicine, Medical School, University of Patras, Patras, Greece
,
Foteini Tsapardonia Department of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Iasonas Tsekourasa Department of Ophthalmology, Medical School, University of Patras, Patras, Greece
,
Andreas A. Argyriouc Saint Andrew’s’ State General Hospital of Patras, Patras, GreeceORCID Iconhttps://orcid.org/0000-0003-2131-7114
ORCID Icon,
Haralabos Kalofonosb Division of Oncology, Department of Medicine, Medical School, University of Patras, Patras, Greece
&
Constantine D. Georgakopoulosa Department of Ophthalmology, Medical School, University of Patras, Patras, GreeceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5646-1370
ORCID Icon show all
Pages 643-648 | Received 02 Jun 2020, Accepted 23 Sep 2020, Published online: 14 Oct 2020

References

  • Hui E. Immune checkpoint inhibitors. J Cell Biol. 2019;218(3):740–741.
  • Wilky BA. Immune checkpoint inhibitors: The Linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6–23.
  • Teufel A, Zhan T, Härtel N, et al. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Lett. 2019;456:80–87.
  • Brahmer JR, Lacchetti C, Schneider BJ, National Comprehensive Cancer Network, et al. National comprehensive cancer network. management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768.
  • Bitton K, Michot JM, Barreau E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019; 202:109–117.
  • Xu Q, Du W, Zhou H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy. Br J Ophthalmol. 2019;103(6):797–801.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
  • Keytruda Summary of product characteristics; [cited 2020 March 11] Available from: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_. en.pdf.
  • Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45(7):1892–1905.
  • June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nat Med. 2017;23(5):540–547.
  • Della Vittoria Scarpati G, Fusciello C, Perri F, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets Ther. 2014;7:203–209.
  • Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294.
  • Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016;4:66
  • Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol. 2015;35(2):144–147.
  • Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–4318.
  • Mori S, Kurimoto T, Ueda K, et al. Optic neuritis possibly induced by anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma. Case Rep Ophthalmol. 2018;9(2):348–356. Jul 20
  • Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859.
  • Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26(3):e46. Apr 12
  • Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51(1):e4–e6.
  • Telfah M, Whittaker TJ, C Doolittle G. Vision loss with pembrolizumab treatment: A report of two cases. J Oncol Pharm Pract. 2019;25(6):1540–1546.
  • Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, et al. Birdshot-like chorioretinopathy associated with pembrolizumab treatment. JAMA Ophthalmol. 2018;136(10):1205–1207.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.